While Dyne Therapeutics Inc has underperformed by -9.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN fell by -71.68%, with highs and lows ranging from $47.45 to $8.15, whereas the simple moving average fell by -73.18% in the last 200 days.
On March 12, 2025, BMO Capital Markets started tracking Dyne Therapeutics Inc (NASDAQ: DYN) recommending Outperform. A report published by Scotiabank on March 07, 2025, Initiated its previous ‘Sector Outperform’ rating for DYN. Robert W. Baird also rated DYN shares as ‘Outperform’, setting a target price of $46 on the company’s shares in an initiating report dated December 13, 2024. RBC Capital Mkts Initiated an Outperform rating on November 26, 2024, and assigned a price target of $45. JP Morgan October 24, 2024d its ‘Overweight’ rating to ‘Neutral’ for DYN, as published in its report on October 24, 2024. Chardan Capital Markets’s report from May 21, 2024 suggests a price prediction of $42 for DYN shares, giving the stock a ‘Buy’ rating. Morgan Stanley also rated the stock as ‘Overweight’.
Analysis of Dyne Therapeutics Inc (DYN)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Dyne Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -88.03% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 15.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and DYN is recording an average volume of 2.28M. On a monthly basis, the volatility of the stock is set at 8.26%, whereas on a weekly basis, it is put at 13.84%, with a loss of -28.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $47.86, showing growth from the present price of $7.49, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 22.80%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.95% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DYN shares are owned by institutional investors to the tune of 80.95% at present.
